Company news
Clene Inc. (NASDAQ:CLNN) news
Clene Inc. news releases on 6ix. Latest, Sep 22, 2026: Clene to Present at Upcoming Investor Conferences
Press releases & updates
Clene to Present at Upcoming Investor Conferences
September 22, 2026
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
September 21, 2026
Clene Announces $4 Million Registered Direct Offering
September 15, 2026
Clene to Present at Upcoming September Investor Conferences
September 3, 2026
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
August 14, 2026
Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval
August 10, 2026
Clene to Present at The Canaccord 46th Annual Growth Conference
July 29, 2026
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
May 14, 2026
Clene Announces $7 Million Underwritten Offering of Common Stock
May 5, 2026
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
May 4, 2026
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
March 11, 2026
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts
February 23, 2026
Clene to Present at the Emerging Growth Conference
January 16, 2026
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
January 12, 2026
Clene Announces Registered Direct Offering of Over $28 Million
January 9, 2026
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
December 3, 2025
Clene to Provide CNM-Au8® ALS Program Update
December 2, 2025
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
November 20, 2025
Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights
November 13, 2025
Clene to Participate in a Panel Discussion at the Maxim Growth Summit
October 15, 2025
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
September 25, 2025
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
September 4, 2025
Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights
August 14, 2025
Clene to Present at the Canaccord 45th Annual Growth Conference
August 5, 2025
Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
June 30, 2025
Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025
June 8, 2025
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights
May 7, 2025
Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
May 7, 2025
Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session
April 8, 2025
Clene to Present at the Jones Healthcare and Technology Innovation Conference
April 1, 2025
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025
March 24, 2025
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
March 24, 2025
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
March 12, 2025
Clene to Present at the 37TH Annual Roth Conference
March 6, 2025
Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11
February 26, 2025
Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction
February 25, 2025
Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan
December 18, 2024
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
December 9, 2024
Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights
November 12, 2024
Clene to Present at Upcoming October Conferences
October 8, 2024
Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility
September 30, 2024
Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules
September 29, 2024
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
September 15, 2024
Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 2, 2024
Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights
August 6, 2024
Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS
August 5, 2024
Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
August 4, 2024
Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS
July 10, 2024
Clene Announces 1-for-20 Reverse Stock Split
July 8, 2024